Table 4.
Patients' characteristics and association with PD-L1 (Dako22C3).
| Characteristics | PD-L1 (Dako22C3) | p value | ||
|---|---|---|---|---|
| <1% (N = 53) | 1-49% (N = 56) | ≥50% (N = 18) | ||
| Age, median (years) | 65 (30-93) | 66 (43-94) | 66 (44-81) | |
| ≤65 | 28 (43.8%) | 27 (42.2%) | 9 (14.1%) | 0.890 |
| >65 | 25 (39.7%) | 29 (46.0%) | 9 (14.3%) | |
| Gender | ||||
| Male | 30 (36.1%) | 41 (49.4%) | 12 (14.5%) | 0.189 |
| Female | 23 (52.3%) | 15 (34.1%) | 6 (13.6%) | |
| Histology | ||||
| Adenocarcinoma | 41 (46.6%) | 36 (40.9%) | 11 (12.5%) | 0.759 |
| SqCC | 4 (25%) | 9 (56.3%) | 3 (18.8%) | |
| Adenosquamous carcinoma | 2 (40.0%) | 2 (40.0%) | 1 (20.0%) | |
| NSCLC | 6 (33.3%) | 9 (50.0%) | 3 (16.7%) | |
| T | ||||
| 1 | 5 (62.5%) | 3 (37.5%) | 0 (0.0%) | 0.566 |
| 2 | 10 (47.6%) | 7 (33.3%) | 4 (19.0%) | |
| 3 | 9 (45.0%) | 10 (50.0%) | 1 (5.0%) | |
| 4 | 28 (39.4%) | 31 (43.7%) | 12 (16.9%) | |
| N | ||||
| 0 | 5 (50.0%) | 4 (40.0%) | 1 (10.0%) | 0.031 |
| 1 | 7 (77.8%) | 2 (22.2%) | 0 (0.0%) | |
| 2 | 15 (62.5%) | 6 (25.0%) | 3 (12.5%) | |
| 3 | 26 (31.0%) | 44 (52.4%) | 14 (16.7%) | |
| M | ||||
| 0 | 10 (45.5%) | 7 (31.8%) | 5 (22.7%) | 0.306 |
| 1 | 43 (41.0%) | 49 (46.7%) | 13 (12.4%) | |
| Stage | ||||
| I/II | 3 (60.0%) | 1 (20.0%) | 1 (20.0%) | 0.568 |
| III | 7 (41.2%) | 6 (35.3%) | 4 (23.5%) | |
| IV | 43 (41.0%) | 49 (46.7%) | 13 (12.4%) | |
| EGFR | ||||
| Mutation | 24 (49.0%) | 21 (42.9%) | 4 (8.2%) | 0.264 |
| Wild type | 22 (36.1%) | 29 (47.5%) | 10 (16.4%) | |
| ALK | ||||
| Positive | 1 (16.7%) | 4 (66.7%) | 1 (16.7%) | 0.412 |
| Negative | 45 (44.1%) | 44 (43.1%) | 13 (12.7%) | |
| PD-L1 (SP142 TC/IC) | ||||
| <1%/<1% | 43 (53.1%) | 35 (43.2%) | 3 (3.7%) | <0.001 |
| Intermediate | 4 (16.7%) | 15 (62.5%) | 5 (20.8%) | |
| ≥50%/>10% | 1 (10.0%) | 1 (10.0%) | 8 (80.0%) | |
| PD-L1 (Dako28-8) | ||||
| <1% | 41 (77.4%) | 11 (20.8%) | 1 (1.9%) | <0.001 |
| 1-49% | 7 (17.5%) | 31 (77.5%) | 2 (5.0%) | |
| ≥50% | 0 (0.0%) | 6 (42.9%) | 8 (57.1%) | |
Figures are numbers with percentages in parentheses, unless otherwise stated. The chi-squared test of independence: categorical variable. NSCLC: non-small cell lung cancer; TC: tumor cells; IC: immune cells.